260 likes | 428 Views
Angelo Avogaro. Università degli Studi di Padova. Universa Universis Patavina Libertas. La carenza di cellule endoteliali progenitrici: un passaggio chiave nell’ambito della patologia cardiovascolare del malato di diabete. Fibrinolysis. Platelets aggregation. Coagulation. Permeability.
E N D
Angelo Avogaro Università degli Studi di Padova Universa Universis Patavina Libertas La carenza di cellule endoteliali progenitrici: un passaggio chiave nell’ambito della patologia cardiovascolare del malato di diabete.
Fibrinolysis Platelets aggregation Coagulation Permeability Adhesiveness Infiammation TXA2 vWF MCP-1 ICAM-1 t-PA Fibrinogen RAGE NO PAI-1 VCAM-1 P-selectin PGI2 TF Thrombomodulin PGI2 VEGF TXA2 PDGF EDHF NO ET-1 TGF-β Vasodilatation Vasocostriction Proliferation
Causes of endothelial dysfunction in Diabetes 1. Impaired Glucose PKC Polyols AGE Hexosamines NAD(P)H Oxidase ROS ADMA BH4 ROS NOS3 L-arginine L-citrulline NO Glycated proteins ROS NAD(P)H Oxidase Vasodilatation
Changes in Coronary segment diameters expressed as percentage of baseline in response to Acetylcholine (Adapted from Nitenberg et al. Diabetes 1993) C vs. D P<0.01 P<0.001 P<0.001 P<0.001 n.s
Postprandial Myocardial Perfusion is impaired in Type 2 Diabetic Patients (Scognamiglio et al. 2005) 15 10 Myocardial Blood Flow 5 0 Baseline Postprandial
Changes in Coronary segment diameters expressed as percentage of baseline in response to Acetylcholine (Adapted from Nitenberg et al. Diabetes 1993) C vs. D P<0.01 P<0.001 P<0.001 P<0.001 n.s
Circulating Endothelial Cells in Cardiovascular Disease (Boos et al. 2006) RF RF CEC CD 133+ CD 146- Blood Vessel
Endothelial Precursor Cells: a novel approach to assess vascular integrity 0.1% to 3.0% of endothelial cells proliferate daily Endothelial cell division may reach 50% of the cells in and around the injured sites Ingram et al. Blood 2005
Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c (McClung et al. 2005)
Major steps of endothelial cell migration Lamalice, L. et al. Circ Res 2007;100:782-794
EPC Endothelial cell apoptosis and -regeneration Regeneration Apoptosis Risk factors Apoptosis
BoneMarrow↔ CirculatingProgenitorCells CD34+ cell pool Bonemarrowcells Peripheral blood Smooth muscle progenitor cells (a-actin+) Endothelial progenitor cells (KDR+) Cardiomyocyte progenitor cells (c-met+/CXCR4+)
Mechanisms of Progenitor Cell Decrease Defective mobilization Decreased survival Increased homing Deranged differentiation Low EPCs Injured endothelium Repair Apoptosis Ischemia VEGF SDF-1 PlGF FGF EPO EPCs From BONE MARROW Differentiation ? Differentiation HSCs Other CD34+ derived phenotypes New vessel growth VSMCs migration Fadini et al. Curr Diabetes Rev 2005
Bone marrow and peripheral blood progenitor cells Bonemarrow and peripheralbloodsampledduring open heartsurgery r = 0.51 p = 0.017
DiabetesMellitus and EPCs (Tepperet al. Circulation 2002; Loomanset al. Diabetes 2004; Fadiniet al. JACC 2005) Culture EPC count Adhesion HbA1c (%) CTRL DM2 EPC count HbA1c (%)
The quantitative analysis revealed a significant decrease in the CPC amount after culture in HG medium (A) Krankel, N. et al. Arterioscler Thromb Vasc Biol 2005;25:698-703
The clinicalsignificanceofEPCs (Fadiniet al. ATVB 2006) PAD: Disease Stage ofRutheford CCA plaqueobstruction
The clinicalsignificanceofEPCs DiseaseMarker – Prediabetes(Fadiniet al Diabetologia 2007)
Reducedsurvival 120 120 110 110 100 100 90 90 EPC / high power field . EPC / high power field . 80 80 70 70 60 60 50 50 Glucose Glucose 0 25 25 0 25 25 P38 inhib - - + P38 inhib - - + * Seeger et al. Circulation 2005 * * * Federici et al. Diabetes 2006
Impairedmobilization (Fadiniet al. Diabetologia 2006) G-CSF 50 mg/kg + SCF 200 mg/kg 5 days
Progressive progenitor cell decline adjusted observed DM DM DM 10- DM N = 425 NGT IFG IGT new <10 20 >20 200 150 100 50 0 CD34+ Cell count -50 -100 -150 -200 -250 -300 Adjustedforage, sex, plasma glucose, HbA1c, BMI, smoke, bloodpressure, lipidprofile, diabeticcomplications and CVD, medications
CD34+ progenitor cells metabolic components Synergistic reduction of CD34+ progenitors at clustering cardiometabolic risk factors Correlation between CD34+ cells and HOMA, a measure of insulin resistance Fadini et al. Eur Heart J 2006
Progenitor Cells and Outcomes in MetSyn Patients n = 214 All events CV events Death * * After correction for age, sex, lipid profile, blood pressure, family history, smoking habit, obesity, CRP, plasma glucose, renal function, baseline CVD, metabolic syndrome, 10-yr Italian risk score. Atherosclerosis in press
The bone marrow connection DIABETES MELLITUS Endothelial progenitor cells CD34+ Sca-1+ c-kit+ Cardiomyocyte progenitor cells Bone marrow defect Smooth muscle progenitor cells CARDIOVASCULAR COMPLICATIONS
Acknowledgments PADOVA EPC Study Group METABOLIC DIVISION Gianpaolo Fadini Saula de Kreutzenberg GENERAL PATHOLOGY Saverio Sartore Mattia Albiero Stefano Schiaffino CLINICAL IMMUNOLOGY Carlo Agostini Elisa Boscaro Partly supported by the Heart Repair consortium